Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer (scientific article)

Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer

Q73235041

Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues

Q74093343

PTEN promoter is methylated in a proportion of invasive breast cancers

Q80594418

Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression

Q81016417

Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1

Q81790772

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Q37129376

Tenets of PTEN tumor suppression

Q37154214

PTEN-mediated pathways and their association with treatment-resistant prostate cancer

Q37394161

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial

Q37662874

Why do cells release vesicles?

Q37691032

Exosomes as biomarker treasure chests for prostate cancer

Q37825112

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Q38467346

PTEN is destabilized by phosphorylation on Thr366.

Q40143795

The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells

Q48362692

First CHO genome.

Q51766116

PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.

Q51789440

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.

Q55466614

Can urinary exosomes act as treatment response markers in prostate cancer?

Q21245467

Microvesicles: mediators of extracellular communication during cancer progression

Q24628728

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN.

Q28305284

Pten is essential for embryonic development and tumour suppression

Q28509238

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Q28513537

Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice

Q28586215

Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs

Q28750201

Cancer statistics, 2007

Q29547293

Cancer statistics, 2009

Q29547625

Exosomes: extracellular organelles important in intercellular communication

Q29620346

Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Q30494717

PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model

Q32069431

A systematic review of the diagnostic accuracy of prostate specific antigen

Q33501864

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

Q33599964

The multiple roles of PTEN in tumor suppression

Q33849727

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

Q34469941

Prostate cancer incidence and mortality rates and trends in the United States and Canada

Q34756568

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Q34763495

The cancer biomarker problem

Q34767213

Microvesicles: messengers and mediators of tumor progression

Q34987500

PTEN controls tumor-induced angiogenesis

Q35282160

Human cancer, PTEN and the PI-3 kinase pathway

Q35812408

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

Q36067596

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

Q36357152

Phosphorylation keeps PTEN phosphatase closed for business

Q37083611

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

prostate cancer

Q181257

P304

page(s)

e70047

P577

publication date

2013-07-25

P1433

published in

PLOS One

Q564954

P1476

title

Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer

P478

volume

Reverse relations

cites work (P2860)

Q88488558	A history of exploring cancer in context
Q59133974	Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy
Q92938641	Circulating microvesicle protein is associated with renal transplant outcome
Q36880469	Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.
Q88881216	Diagnostic value of microRNAs derived from exosomes in bronchoalveolar lavage fluid of early-stage lung adenocarcinoma: A pilot study
Q38967191	Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes
Q38624837	Emerging techniques in the isolation and characterization of extracellular vesicles and their roles in cancer diagnostics and prognostics
Q92200712	Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study
Q64279946	Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients
Q33363486	Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression
Q35834473	Exosomes in cancer: small particle, big player
Q38264347	Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle.
Q33357387	Exosomes in prostate cancer: putting together the pieces of a puzzle
Q33871862	Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases.
Q38781015	Extracellular Vesicles in Brain Tumor Progression
Q55342189	Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management.
Q30238818	Extracellular Vesicles: How the External and Internal Environment Can Shape Cell-To-Cell Communication.
Q38898891	Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation
Q26770045	Extracellular vesicle transfer of cancer pathogenic components
Q36081720	Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases
Q47622685	Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside
Q93009737	Extracellular vesicles in urologic malignancies-Implementations for future cancer care
Q38379177	Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day
Q35440744	Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology
Q89848849	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis
Q37269014	Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer
Q38275632	Identification of intrinsically disordered regions in PTEN and delineation of its function via a network approach
Q38174601	Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity
Q64056707	Intercellular Vesicular Transfer by Exosomes, Microparticles and Oncosomes - Implications for Cancer Biology and Treatments
Q27005677	Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN
Q33624594	Microvesicles Contribute to the Bystander Effect of DNA Damage
Q36356460	Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel
Q27021174	Novel RNA markers in prostate cancer: functional considerations and clinical translation
Q38925313	PTEN secretion in exosomes.
Q38406254	PTEN: a yin-yang master regulator protein in health and disease
Q36737927	Prostasomes as a source of diagnostic biomarkers for prostate cancer
Q35165208	Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling
Q27022790	Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders
Q36967232	Systematic analysis of the PTEN 5' leader identifies a major AUU initiated proteoform
Q28299026	The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy
Q35807725	The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy.
Q38268801	The emerging role of extracellular vesicles as biomarkers for urogenital cancers.
Q38171466	The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers
Q33823191	The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis
Q38234994	The yin-yang of microvesicles (exosomes) in cancer biology

P819	ADS bibcode	2013PLoSO...870047G
P356	DOI	10.1371/JOURNAL.PONE.0070047
P932	PMC publication ID	3723640
P698	PubMed publication ID	23936141
P5875	ResearchGate publication ID	255736979